TomoTherapy Incorporated announced that two of the first TomoTherapy® TomoHD™ treatment systems in the United States were purchased and installed by the University of Virginia Health System. Clinicians began using one of the TomoHD treatment systems to treat patients in early April at the newly opened Emily Couric Clinical Cancer Center on University of Virginia’s flagship campus in Charlottesville. The second system was installed and is operated in a partnership between the University of Virginia Health System and the Culpeper Regional Hospital Radiation Oncology Service in Culpeper.
“We have extensive experience with the use of TomoTherapy technology here at University of Virginia, and the evolution to the TomoHD treatment system is a natural extension of our capabilities,” said Paul Read, MD, PhD, vice chair of University of Virginia’s Department of Radiation Oncology. “By installing a TomoHD system at our Charlottesville campus, we will have more flexibility to treat complex cancers—such as head and neck tumors—with precision using the TomoTherapy platform’s image-guided radiation therapy capabilities. And for our partner at the community cancer center in Culpeper, TomoHD is an ideal multipurpose device for delivering radiation therapy to patients with common cancers, such as those of the breast or prostate, who don’t want to travel great distances for cutting-edge care.”
The Emily Couric Clinical Cancer Center opened on April 4 and is designed to provide patients with therapies and comprehensive cancer care. Within a week of the center’s opening, University of Virginia clinicians were treating on average 20 patients a day on the TomoHD system, with a focus on head and neck tumors and hypofractionated courses of radiation for prostate cancer.
With the TomoHelical mode of delivery, small “beamlets” of radiation are delivered in a helical pattern from any point in a 360° radius around the patient. This rotational delivery pattern enables radiation to be delivered from all angles around a patient, helping to target dose directly to the tumor while avoiding critical organs. The TomoDirect delivery mode facilitates a non-rotational delivery option that enables clinicians to quickly plan and deliver advanced TomoTherapy radiation treatments with a series of linear beam paths, rather than a single helical delivery path, thereby improving efficiency in the treatment of more common or less complex tumors.
“We are proud to work with the University of Virginia to bring the benefits of TomoTherapy technology to patients throughout the [commonwealth] of Virginia,” said Fred Robertson, MD, president and CEO of TomoTherapy. “With the installation of the TomoHD systems in these two new cancer centers, the UVA Health System is showing its commitment to offering the highest level of care to the broad range of communities it serves.”